Newsig · CNBC
Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.
Why it matters
LLY (Eli Lilly) · Why linked: The news is directly about Eli Lilly's combo obesity regimen showing strong mid-stage results. Market context: Positive Phase 2 weight loss data and planned Phase 3 trials support the company's obesity drug pipeline and long-term revenue outlook.
Reaction tracking
A completed 24-hour reaction record is not available for this story yet. Newsig only publishes measured price movement when the required market data is present.
Curated by Newsig — News in. Signal out.
How the reaction data is measured · Editorial policy